Brief: Aclaris Therapeutics Says Positive Full Top Line Results From Phase 1A Clinical Trial Of ATI-055

Aclaris Therapeutics

28/04/2026 11:32

April 28 (Reuters) - Aclaris Therapeutics Inc ACRS.O:

ACLARIS THERAPEUTICS ANNOUNCES POSITIVE FULL TOP LINE FIRST-IN-HUMAN RESULTS FROM PHASE 1A HEALTHY VOLUNTEER CLINICAL TRIAL OF ATI-052, A NOVEL POTENTIAL FIRST-IN-CLASS ANTI-TSLP/IL-4RΑ BISPECIFIC ANTIBODY, AND ANNOUNCES LICHEN PLANUS AS LEAD INDICATION FOR ATI-2138, AN ORAL ITK/JAK3 INHIBITOR

ACLARIS THERAPEUTICS INC - ATI-052 WELL TOLERATED WITH FAVORABLE SAFETY PROFILE IN PHASE 1A TRIAL

ACLARIS THERAPEUTICS INC: NO IMPACT OF ANTI-DRUG ANTIBODIES (ADA) ON PK OR PD HAS BEEN OBSERVED IN THIS TRIAL

ACLARIS THERAPEUTICS INC - TO INITIATE PHASE 2B PROGRAM WITH ATI-052 IN ASTHMA IN Q4 2026

ACLARIS THERAPEUTICS INC - ENROLLMENT ONGOING IN PHASE 1B TRIALS OF ATI-052; TOP LINE RESULTS EXPECTED H2 2026

Source text: ID:nGNX7xFdpg

Further company coverage: ACRS.O

 ((Reuters.Briefs@thomsonreuters.com;))